odanacatib (MK-0822) / Merck (MSD)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
odanacatib (MK-0822) / Merck (MSD)
NCT00691899 / 2008-002120-29: A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Withdrawn
3
0
US
odanacatib, MK0822, placebo (unspecified)
Merck Sharp & Dohme LLC
Prostate Cancer
09/08
09/08
NCT00692458 / 2008-002119-42: A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

Withdrawn
3
0
US
Comparator: odanacatib, Comparator: placebo
Merck Sharp & Dohme LLC
Breast Cancer
09/08
09/08
NCT00729183 / 2008-004504-31: Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)

Completed
3
214
NA
Odanacatib, MK-0822, Placebo, Vitamin D3, Calcium supplement, calcium carbonate, calcium citrate
Merck Sharp & Dohme LLC
Osteoporosis
03/10
03/11
NCT00529373 / 2011-005514-10: A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Terminated
3
16071
NA
Odanacatib, MK-0822, Placebo for Odanacatib, Vitamin D3, Calcium carbonate, Calcium supplements
Merck Sharp & Dohme LLC
Postmenopausal Osteoporosis
11/12
02/17
MK-0822-053, NCT01120600: A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis

Completed
3
294
NA
Odanacatib, MK-0822, Placebo for Odanacatib, Vitamin D3, Calcium carbonate
Merck Sharp & Dohme LLC
Osteoporosis
07/13
07/13
2010-019454-41: A Phase III Study to Assess the Safety and Efficacy of Odanacatib (MK 0822) in Men with Osteoporosis Treated with Vitamin D and Calcium

Completed
3
360
Europe, RoW
MK-0822; Chemical name: N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4’-(methylsulfo, MK-0822, Tablet
Merck Sharp & Dohm Corp., Merck Sharp & Dohme Corp., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme B.V., MERCK & CO., INC., , Merck & Co., Inc.
osteoporosis, osteoporosis, Body processes [G] - Bones and nerves physological processes [G11]
 
 
NCT01803607: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)

Terminated
3
135
NA
odanacatib, MK-0822, placebo to odanacatib
Merck Sharp & Dohme LLC
Osteoporosis
11/14
11/14
NCT01552122: Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)

Withdrawn
3
0
US
Odanacatib, MK-0822, Alendronate, Alendronate Sodium, Fosamax, Placebo (odanacatib), Cholecalciferol (Vitamin D3), Calcium carbonate, Placebo (alendronate)
Merck Sharp & Dohme LLC
Osteoporosis, Postmenopausal Osteoporosis
02/15
02/15
2007-002693-66: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium

Completed
3
16300
Europe, RoW
MK-0822; Chemical name: N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4’-(methylsulfo, MK-0822, Tablet, VITAMINA D3 500000UI/G POLV1KG
MERCK SHARP & DOHME CORP., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc., Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A., Laboratoires Merck Sharp & Dohme - Chibret, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck & Co., Inc, MERCK SHARP DOHME ITALIA S.P.A., Merck & Co., Inc., MERCK SHARP & DOHME CORP., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a Subsidiary of Merck and Co.,, , Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A., Merck & Co.,Inc., MERCK SHARP & DOHME CORP., a subsidiary of Merck & Co., Inc, Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc.
Postmenopausal Osteoporosis, Postmenopausal Osteoporosis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
2005-001511-22: A Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) vs placebo in the Treatment of Women With Osteoporosis

Completed
2/3
375
Europe, RoW
L-001037536, MK-0822, Tablet
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,, Merck Sharp & Dohme Corp., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp.,
Postmenopausal Osteoporosis
 
 

Download Options